Enfusion (NYSE:ENFN - Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens on Monday, November 4th. Analysts expect Enfusion to post earnings of $0.06 per share for the quarter. Enfusion has set its FY 2024 guidance at EPS.Individual that wish to register for the company's earnings conference call can do so using this link.
Enfusion (NYSE:ENFN - Get Free Report) last released its earnings results on Tuesday, August 6th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01). Enfusion had a return on equity of 6.17% and a net margin of 1.98%. The business had revenue of $49.46 million for the quarter, compared to the consensus estimate of $50.27 million. On average, analysts expect Enfusion to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Enfusion Price Performance
Shares of NYSE:ENFN traded up $0.20 on Monday, hitting $9.16. 176,588 shares of the company's stock were exchanged, compared to its average volume of 366,932. Enfusion has a 12 month low of $7.52 and a 12 month high of $10.45. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of 229.81, a price-to-earnings-growth ratio of 2.46 and a beta of 0.92. The business's 50 day simple moving average is $8.66 and its two-hundred day simple moving average is $8.86.
Enfusion Company Profile
(
Get Free Report)
Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.
Further Reading
Before you consider Enfusion, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enfusion wasn't on the list.
While Enfusion currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.